Bain Capital said the deal came about following several recent initiatives by the Japanese government and regulators to ...

Private equity firm Bain Capital (BCSF) is paying $3.4 billion to buy a 350-year-old Japanese drugs group fighting diabetes ...

The Japanese chemical company has agreed to sell its pharmaceutical business to Bain Capital for more than $3 billion, in a ...

Bain said its decision to buy Mitsubishi Tanabe is due to the “strong growth potential” of Japan’s healthcare industry.

U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 billion yen ($3.4 billion), ...

Tanabe Pharma focuses on therapeutic areas such as immunology and inflammation, vaccines, diabetes, and central nervous ...

Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation ("Tanabe Pharma", "MTPC" or "the Company") ...

Bain Capital kicked off the bidding war for MLC-owner Insignia Financial and has certainly pulled out all the stops to assemble an experienced team to assist it in winning the $3.1bn contest.

Bain Capital Specialty Finance has shown strong performance with impressive earnings and solid portfolio quality. Read why I ...

Following rumblings of a private equity bidding war late last year, Bain Capital has emer | Bain Capital is laying out 510 ...

Bain Capital Private Equity has proposed to acquire the remaining shares of surgical facility operator Surgery Partners it ...